Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages

  Rinderknecht, Stephen ^a   Michaels, Marian G ^b   Blatter, Mark ^c   Gaglani, Manjusha ^d   Andrews, Wilson ^e   Abughali, Nazha ^f   Chandreshekaran, Vijayalakshmi ^g   Trofa, Andrew F ^g  

^a Iowa Health Physicians   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c Primary Physicians Research Inc   (United States)

^d TEXAS A M COLLEGE OF MEDICINE   (United States)

^e Pediatrics and Adolescent Medicine PA   (United States)

^f METROHEALTH MEDICAL CENTER   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

coadministration; hepatitis A vaccine; immunogenicity; measles mumps rubella vaccine; safety; varicella vaccine

Indexed keywords

HEPATITIS A VACCINE; INACTIVATED VACCINE; MEASLES MUMPS RUBELLA VACCINE;

ANOREXIA; ARTICLE; CHILD; CONTROLLED STUDY; DROWSINESS; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE CONVULSION; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; IRRITABILITY; MALE; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; OTITIS MEDIA; PAIN; PARTOID GLAND SWELLING; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SALIVARY GLAND DISEASE; SEROLOGY; SIDE EFFECT;

EID: 80052916527     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31822256a5     Document Type: Article

References (20)

1. World Health Organization. Hepatitis A. Fact Sheet No. 328, May 2008. Available at: http://www.who.int/mediacentre/factsheets/fs328/en/index.html. Accessed August 2010.
2. Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev. 2006;28:101-111. (Pubitemid 44289093)
3. Daniels D, Grytdal S, Wasley A; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009;58:1-27.
4. Fiore AE, Wasley A, Bell BP; Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1-23.
5. Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immuno-genicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J. 2006;25:912-919. (Pubitemid 44510586)
6. Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and Haemophilus influenzae type b vaccines to children less than 2 years of age. Pediatrics. 2006;118:602-609.
7. Trofa A, Levin M, Marchant CD, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with a pneumo-coccal conjugate vaccine in healthy children 15 months of age. Pediatr Infect Dis J. 2008;27:658-660.
8. Trofa AF, Klein NP, Paul IM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with diphtheria-teta-nus- acellular pertussis and Haemophilus influenzae type b vaccines in children aged 15 months. Pediatr Infect Dis J. 2011;30:e164-169.
9. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA. 2005;294:202-210. (Pubitemid 41043790)
10. Chodick G, Heymann AD, Ashkenazi S, et al. Long-term trends in hepatitis A incidence following the inclusion of hepatitis A vaccine in the routine nationwide immunization program. J Viral Hep. 2008;15:62-65.
11. Dominguez A, Oviedo M, Carmona G, et al. Epidemiology of hepatitis A before and after the introduction of a universal vaccination programme in Catalonia, Spain. J Viral Hep. 2008;15(suppl 2):51-56.
12. Vaccino MN. Incidence of hepatitis A in Argentina after vaccination. J Viral Hep. 2008;15(suppl 2):47-50.
13. Barkai G, Belmaker I, Givon-Lavi N, et al. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J. 2009;28:391-393.
14. Zhou F, Shefer A, Weinbaum C, et al. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine. 2007;25: 3581-3587. (Pubitemid 46584760)
15. Hall-Baker PA, Nieves E Jr, Jajosky RA, et al. Summary of notifiable diseases-United States, 2008. Morb Mortal Wkly Rep. 2010;57:1-94.
16. Centers for Disease Control and Prevention (CDC). Hepatitis A vaccination coverage among U.S. children aged 12-23 months-immunization information system sentinel sites, 2006-2009. Morb Mortal Wkly Rep. 2010; 59:776-779.
17. Kroger AT, Atkinson WL, Marcuse EK, et al. Advisory Committee on Immunization Practices (ACIP); Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-15):1-48.
18. White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991;87:604-610.
19. Usonis V, Bakasenas V, Kaufhold A, et al. Reactogenicity and immuno-genicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J. 1999;18:42-48. (Pubitemid 29055268)
20. Shinefield HR, Black SB, Staehle BO, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002;21:555-561. (Pubitemid 34632578)